Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Mol Cell Endocrinol ; 531: 111318, 2021 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-33989716

RESUMEN

The aim of the present study is to assess whether low level laser therapy (LLLT) can protect ovaries from chemotherapy-induced gonadotoxicity using a mice model of premature ovarian failure induced by cyclophosphamide (CTX). LLLT (64 J/cm2) increased the number of antral follicles whilst decreasing the number of atretic follicles compared to CTX alone. LLLT increased the number of primordial follicles compared with those in the CTX group but they did not differ from those in the control group. LLLT treatment increased the number of AMH-positive follicles compared to CTX alone. LLLT application increased ovarian weight, serum progesterone concentration and P450scc protein levels compared to CTX alone. LLLT reduced the apoptosis in antral follicles and the BAX/BCL-2 ratio compared to CTX alone. Vascular morphology, analysed by CD31 and α-SMA immunostaining, was restored in LLLT-treated ovaries compared to CTX alone. In conclusion, application of LLLT prior to CTX might serve as a promising and novel protocol to preserve female fertility in cancer survivors.


Asunto(s)
Ciclofosfamida/efectos adversos , Terapia por Luz de Baja Intensidad/métodos , Ovario/metabolismo , Insuficiencia Ovárica Primaria/prevención & control , Animales , Sistema Enzimático del Citocromo P-450/metabolismo , Modelos Animales de Enfermedad , Femenino , Humanos , Ratones , Tamaño de los Órganos/efectos de los fármacos , Tamaño de los Órganos/efectos de la radiación , Ovario/efectos de los fármacos , Ovario/efectos de la radiación , Insuficiencia Ovárica Primaria/inducido químicamente , Insuficiencia Ovárica Primaria/metabolismo , Progesterona/sangre
2.
Gynecol Oncol ; 160(2): 619-624, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33309416

RESUMEN

Cancer treatment-induced bone loss is a known side effect of cancer therapy that increases the risk of osteoporosis and bone fracture. Women with gynecologic cancer are at increased risk of bone loss secondary to the combined effect of oophorectomy and adjuvant therapies. Data regarding bone loss in women with gynecologic cancers are overall lacking compared to other cancer populations. Consequently, guidelines for osteoporosis screening in women with cancer are largely based on data generated among non-gynecologic cancer survivors. This article reviews current available data of bone health in women with gynecologic cancer, summarizes best-available guidelines for screening for osteoporosis in women with cancer, and provides guidance for osteoporosis screening in women with gynecologic cancers based on best available evidence.


Asunto(s)
Densidad Ósea/fisiología , Supervivientes de Cáncer/estadística & datos numéricos , Neoplasias de los Genitales Femeninos/terapia , Tamizaje Masivo/normas , Osteoporosis/diagnóstico , Absorciometría de Fotón , Antineoplásicos Hormonales/efectos adversos , Densidad Ósea/efectos de los fármacos , Densidad Ósea/efectos de la radiación , Quimioterapia Adyuvante/efectos adversos , Quimioterapia Adyuvante/métodos , Medicina Basada en la Evidencia/normas , Femenino , Neoplasias de los Genitales Femeninos/complicaciones , Neoplasias de los Genitales Femeninos/mortalidad , Humanos , Menopausia/efectos de los fármacos , Menopausia/metabolismo , Menopausia/efectos de la radiación , Osteoporosis/epidemiología , Osteoporosis/etiología , Osteoporosis/metabolismo , Ovario/efectos de los fármacos , Ovario/metabolismo , Ovario/efectos de la radiación , Ovario/cirugía , Guías de Práctica Clínica como Asunto , Radioterapia Adyuvante/efectos adversos , Factores de Riesgo , Salpingooforectomía/efectos adversos , Supervivencia
3.
Sci Rep ; 10(1): 13551, 2020 08 11.
Artículo en Inglés | MEDLINE | ID: mdl-32782329

RESUMEN

Radiotherapy is a well-known cause of premature ovarian failure (POF). Therefore, we investigated the molecular influence of genistein (GEN) on the ovarian reserve of rats exposed to ϒ-radiation. Female Sprague Dawley rats were exposed to a 3.2 Gy γ-radiation to induce POF and/or treated with either GEN (5 mg/kg, i.p.) or Ethinyl estradiol (E2; 0.1 mg/kg, s.c.), once daily for 10 days. GEN was able to conserve primordial follicles stock and population of growing follicles accompanied with reduction in atretic follicles. GEN restored the circulating estradiol and anti-Müllerian hormone levels which were diminished after irradiation. GEN has potent antioxidant activity against radiation-mediated oxidative stress through upregulating endogenous glutathione levels and glutathione peroxidase activity. Mechanistically, GEN inhibited the intrinsic pathway of apoptosis by repressing Bax expression and augmenting Bcl-2 expression resulted in reduced Bax/Bcl-2 ratio with subsequent reduction in cytochrome c and caspase 3 expression. These promising effects of GEN are associated with improving granulosa cells proliferation. On the molecular basis, GEN reversed ovarian apoptosis through up-regulation of ER-ß and FOXL-2 with downregulation of TGF-ß expression, therefore inhibiting transition of primordial follicles to more growing follicles. GEN may constitute a novel therapeutic modality for safeguarding ovarian function of females' cancer survivors.


Asunto(s)
Apoptosis , Receptor beta de Estrógeno/metabolismo , Proteína Forkhead Box L2/metabolismo , Genisteína/farmacología , Ovario/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Factor de Crecimiento Transformador beta/metabolismo , Animales , Antioxidantes/farmacología , Receptor beta de Estrógeno/genética , Femenino , Proteína Forkhead Box L2/genética , Regulación de la Expresión Génica , Ovario/patología , Ovario/efectos de la radiación , Fitoestrógenos/farmacología , Radiación Ionizante , Ratas , Ratas Sprague-Dawley , Factor de Crecimiento Transformador beta/genética
4.
Int J Radiat Biol ; 95(11): 1529-1542, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31314632

RESUMEN

Evaluation of the modulatory effect of ethanolic extract of Alocasia indica tuber (EEAIT) against γ-irradiation induced ovarian and uterine toxicity. Extract preparation was done by 80% hydro-ethanol using Soxhlet apparatus. EEAIT was administered to female Swiss albino mice (n = 5) daily (200 and 400 mg/kg body weight/d) for 7 days before γ-irradiation exposure (2.9 Gy). FSH, LH, estrogen, progesterone, cytokine levels, and oxidative stress parameters were measured after 24 hours of γ-irradiation. Histology, folliculogenesis, viability of granulosa cells, ROS measurement by flow cytometry, western blot of P450scc, P45017A1, 3ß HSD and SF 1 were also performed. In addition, fertility status was assessed by fecundability and fecundity. The results showed that EEAIT exhibit a strong radioprotective activity by reducing the oxidative stress and thereby restored the ovarian and uterine alterations. EEAIT also improved the abnormality in follicle development, restored altered gonadal hormones and cytokines levels, increase the fertility status, reducing ROS level of granulosa cells with increasing granulosa cells viability and steroidogenic enzyme activity as compared to control. So EEAIT showed a radioprotective effect on γ-irradiation induced ovarian and uterine damage. Our results suggested that Alocasia indica tuber can be a potential radioprotector to prevent female infertility.


Asunto(s)
Alocasia/química , Ovario/efectos de los fármacos , Extractos Vegetales/farmacología , Traumatismos por Radiación/prevención & control , Protectores contra Radiación/farmacología , Útero/efectos de los fármacos , Animales , Antioxidantes/metabolismo , Catalasa/metabolismo , Supervivencia Celular/efectos de la radiación , Citocinas/metabolismo , Etanol/química , Femenino , Fertilidad/efectos de la radiación , Rayos gamma , Células de la Granulosa/efectos de la radiación , Malondialdehído/metabolismo , Ratones , Óxido Nítrico/metabolismo , Ovario/efectos de la radiación , Estrés Oxidativo , Especies Reactivas de Oxígeno/metabolismo , Superóxido Dismutasa/metabolismo , Útero/efectos de la radiación
5.
J Photochem Photobiol B ; 194: 6-13, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30897401

RESUMEN

Follicular cystic ovary disease is a common reproductive disorder in women and females of domestic animals, characterized by anovulation and the persistence of follicle is a common cause of reproductive failure in mammalian. Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism (HA), chronic anovulation and polycystic ovaries, and it is a common reproductive endocrine disease with clinical manifestations including hirsutism, acne, infertility and obesity that can affect 5-20% of women in their reproductive age. Photobiomodulation (PBM) has been investigated and used in clinical practice, related to biomodulatory influences on cellular functions in animals and humans, both in vivo and in vitro. In this study, we include endocrine and reproductive features in a rat model for PCOS and the effects of PBM on ovarian activities. Forty-five adult female Wistar rats PCOS-induced by a single dose of the estradiol valerate (EV) were used in the study. After the EV injection for PCO induction, rats were divided into 9 groups (n = 5/group) named C30, C45 and C60 (Control group), S30, S45 and S60 (PCO group) and L30, L45 and L60 (PCO/Laser group). The rats were irradiated with laser 3 times/week. The results shown that EV PCO-induced rats had increased body mass, reduced ovary mass, and reduced GSI. The plasma levels of P4 and T were increased, and the LH plasma level was decreased by PBM stimulation. The number of ovarian follicles and corpus luteum were increased, and the number of ovarian cysts was decreased by PBM stimulation. Thus, reproductive and endocrine characteristics were modulated by PBM.


Asunto(s)
Terapia por Luz de Baja Intensidad , Ovario/fisiopatología , Ovario/efectos de la radiación , Síndrome del Ovario Poliquístico/radioterapia , Animales , Cuerpo Lúteo/patología , Cuerpo Lúteo/efectos de la radiación , Ciclo Estral/efectos de la radiación , Femenino , Hormonas/sangre , Ovario/patología , Síndrome del Ovario Poliquístico/sangre , Síndrome del Ovario Poliquístico/patología , Síndrome del Ovario Poliquístico/fisiopatología , Ratas , Ratas Wistar
6.
Poult Sci ; 98(6): 2439-2447, 2019 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-30668853

RESUMEN

We evaluated the effect of photoperiod on ovarian morphology, reproductive hormone secretion, and hormone receptor mRNA expression in layer ducks during the pullet phase. A total of 480 71-d-old Jinding layer ducks were randomly divided into 5 groups that received 6L (hours of light):18D (hours of darkness), 8L:16D, 10L:14D, 12L:12D, or 14L:10D, respectively. Each group had 6 replicates with 16 birds each. The photoperiod feeding trial lasted 80 d until 150 d of age. The age at first egg (AFE), the total number, and weight of eggs increased linearly with increasing photoperiods (P < 0.05); lower values of AFE occurred with photoperiods ≥8 h, whereas a higher total number and weight of eggs occurred with photoperiods ≥10 h, compared with 6L:18D (P > 0.05). Oviduct weight, ovary percentage, and initial and bare stroma (weight and percentage) increased quadratically with increasing photoperiods (P < 0.05), and 10.24, 10.01, and 10.10 h were the optimal photoperiods for oviduct weight, bare stroma (follicles ≥2 mm in diameter removed) weight, and bare stroma percentage, respectively, as calculated from reliable regression equations (R2 ≥ 0.5791). Compared with 6L:18D, 10L:14D had a higher total large white follicle weight, small yellow follicle number, and weight (P < 0.05). In addition, higher serum levels of follicle-stimulating hormone, luteinizing hormone, and progesterone were observed with ≥10-h photoperiods (P < 0.05), as were levels of hormone receptor mRNA expression in ovarian follicles (P < 0.05), with the highest values for both measures at 10L:14D. In the hypothalamus, mRNA expression of gonadotropin-releasing hormone increased in ≥8-h photoperiods, with the highest value at 10L:14D. In contrast, gonadotropin-inhibitory hormone increased in photoperiods ≥12 h (P < 0.05). In conclusion, an appropriate photoperiod led to early sexual maturity and improved the development of reproductive organs and ovarian follicles through effects on reproductive hormones and their receptors; 10 to 10.24 h is an adequate photoperiod for layer ducks during the pullet phase.


Asunto(s)
Patos/fisiología , Ovario/efectos de la radiación , Hormonas Peptídicas/sangre , Fotoperiodo , Progesterona/sangre , Maduración Sexual/efectos de la radiación , Animales , Patos/anatomía & histología , Patos/crecimiento & desarrollo , Femenino , Hormona Liberadora de Gonadotropina/metabolismo , Hipotálamo/metabolismo , Ovario/anatomía & histología , Ovario/crecimiento & desarrollo , ARN Mensajero/metabolismo , Distribución Aleatoria , Receptores de Péptidos/metabolismo , Receptores de Progesterona/metabolismo , Maduración Sexual/fisiología
7.
Prog Biophys Mol Biol ; 145: 10-18, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-30500339

RESUMEN

It is known that LLLT has beneficial effects on several pathological conditions including wound healing, pain and inflammation. LLLT modulates biological processes, including cell proliferation, apoptosis and angiogenesis. In the present study, we examined the effect of local application of LLLT on follicular dynamics, ovarian reserve, AMH expression, progesterone levels, apoptosis, angiogenesis, and reproductive outcome in adult mice. LLLT (200 J/cm2) increased the percentage of primary and preantral follicles, whilst decreasing the percentage of corpora lutea compared to control ovaries. LLLT-treated ovaries did not exhibit any changes regarding the number of primordial follicles. We observed a higher percentage of AMH-positive follicles (in early stages of development) in LLLT-treated ovaries compared to control ovaries. LLLT reduced the P4 concentration and the apoptosis in early antral follicles compared to control ones. LLLT caused a reduction in the endothelial cell area and an increase in the periendothelial cell area in the ovary. Additionally, LLLT was able to improve oocyte quality. Our findings suggest that local application of LLLT modulates follicular dynamics by regulating apoptosis and the vascular stability in mouse ovary. In conclusion, these data indicate that LLLT might become a novel and useful tool in the treatment of several pathologies, including female reproductive disorders.


Asunto(s)
Hormona Antimülleriana/biosíntesis , Apoptosis/efectos de la radiación , Terapia por Luz de Baja Intensidad , Neovascularización Fisiológica/efectos de la radiación , Ovario/efectos de la radiación , Animales , Línea Celular , Proliferación Celular/efectos de la radiación , Cuerpo Lúteo/efectos de la radiación , Femenino , Fertilización In Vitro/efectos de la radiación , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Folículo Ovárico/citología , Folículo Ovárico/efectos de la radiación , Ovario/irrigación sanguínea , Ovario/citología , Ovario/metabolismo , Progesterona/biosíntesis , Superovulación/efectos de la radiación
8.
Adv Clin Exp Med ; 27(7): 907-911, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29952147

RESUMEN

BACKGROUND: There is no study of whether the dysplastic changes in the ovarian surface epithelium of X-ray-exposed rats during hysterosalpingography (HSG) decrease or not with the use of Lipiodol and melatonin given both intraperitoneally (i.p.) and into the suspensorium ovarii. OBJECTIVES: We investigated the restorative effects of melatonin and Lipiodol administration during the HSG procedure on the dysplastic changes in the ovarian surface epithelium of X-ray-exposed rats. MATERIAL AND METHODS: A total of 50 Wistar rats with regular estrous cycles were randomly divided into 5 groups. Group 1 was the control group. In other groups, X-ray was applied (group 2), 0.1 mL Lipiodol was applied to each uterine horn (group 3), 20 mg/kg intraperitoneal melatonin application was followed by 0.1 mL Lipiodol administration to each uterine horn after 15 min (group 4), and 20 mg/kg melatonin was administered to the ligamentum suspensorium ovarii, followed by 0.1 mL Lipiodol application to each uterine horn after 15 min (group 5). The rats in groups 2-5 were exposed to whole body radiation 3 times. After 3 h, the abdomens of all rats were reopened and left oophorectomy was performed. RESULTS: The presence of nucleoli and mitosis values were found similar among the groups. All other parameters were significantly higher in group 2 compared to other groups, except for the presence of nucleoli and mitosis values (p < 0.05). The presence of hyperchromasia and the total score were found to be the highest in group 2, followed by group 3, when compared to other groups (p < 0.05). It was detected that the detrimental effects of X-ray exposure diminished with Lipiodol use, and were further reduced by the use of melatonin in combination. CONCLUSIONS: We suggest that the use of melatonin and Lipiodol during HSG may prevent the carcinogenic changes exerted by radiation on the ovarian surface epithelium.


Asunto(s)
Antioxidantes/farmacología , Epitelio/efectos de los fármacos , Histerosalpingografía/efectos adversos , Melatonina/farmacología , Ovario/efectos de los fármacos , Traumatismos por Radiación/prevención & control , Animales , Medios de Contraste/farmacología , Epitelio/efectos de la radiación , Aceite Etiodizado/farmacología , Femenino , Ovario/efectos de la radiación , Traumatismos por Radiación/etiología , Ratas , Ratas Wistar
9.
Toxicol Lett ; 282: 64-70, 2018 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-29024790

RESUMEN

INTRODUCTION: An increased health problem in industrialised countries is the contemporary concern of public and scientific community as well. This has been attributed in part to accumulated environmental pollutants especially radioactive substances and the use of nuclear power plants worldwide. However, the outcome of chronic exposure to low doses of a radionuclide such as uranium remains unknown. Recently, a paradigm shift in the perception of risk of radiotoxicology has emerged through investigating the possibility of transmission of biological effects over generations, in particular by epigenetic pathways. These processes are known for their crucial roles associated with the development of several diseases. OBJECTIVE: The current work investigates the epigenetic effect of chronic exposure to low doses of uranium and its inheritance across generations. Materials and Methods To test this proposition, a rodent multigenerational model, males and females, were exposed to a non-toxic concentration of uranium (40mgL-1 drinking water) for nine months. The uranium effects on were evaluated over three generations (F0, F1 and F2) by analysing the DNA methylation profile and DNMT genes expression in ovaries and testes tissues. RESULTS: Here we report a significant hypermethylation of testes DNA (p <0.005) whereas ovaries showed hypomethylated DNA (p <0.005). Interestingly, this DNA methylation profile was significantly maintained across generations F0, F1 and F2. Furthermore, qPCR results of both tissues imply a significant change in the expression of DNA methyltransferase genes (DNMT 1 and DNMT3a/b) as well. CONCLUSION: Altogether, our work demonstrates for the first time a sex-dependance and inheritance of epigenetic marks, DNA methylation, as a biological response to the exposure to low doses of uranium. However, it is not clear which type of reproductive cell type is more responsive in this context.


Asunto(s)
Metilación de ADN/efectos de la radiación , Epigénesis Genética/efectos de la radiación , Ovario/efectos de la radiación , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Testículo/efectos de la radiación , Uranio/toxicidad , Animales , Relación Dosis-Respuesta en la Radiación , Femenino , Regulación del Desarrollo de la Expresión Génica/efectos de la radiación , Masculino , Ovario/metabolismo , Embarazo , Efectos Tardíos de la Exposición Prenatal/genética , Ratas , Caracteres Sexuales , Testículo/metabolismo
10.
Reproduction ; 154(2): 123-133, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28528322

RESUMEN

Astronauts are exposed to charged particles during space travel, and charged particles are also used for cancer radiotherapy. Premature ovarian failure is a well-known side effect of conventional, low linear energy transfer (LET) cancer radiotherapy, but little is known about the effects of high LET charged particles on the ovary. We hypothesized that lower LET (16.5 keV/µm) oxygen particles would be less damaging to the ovary than we previously found for iron (LET = 179 keV/µm). Adult female mice were irradiated with 0, 5, 30 or 50 cGy oxygen ions or 50 cGy oxygen plus dietary supplementation with the antioxidant alpha lipoic acid (ALA). Six-hour after irradiation, percentages of ovarian follicles immunopositive for γH2AX, a marker of DNA double strand breaks, 4-HNE, a marker of oxidative lipid damage and BBC3 (PUMA), a proapoptotic BCL-2 family protein, were dose dependently increased in irradiated mice compared to controls. One week after irradiation, numbers of primordial, primary and secondary follicles per ovary were dose dependently decreased, with complete absence of follicles in the 50 cGy groups. The ED50 for primordial follicle destruction was 4.6 cGy for oxygen compared to 27.5 cGy for iron in our previous study. Serum FSH and LH concentrations were significantly elevated in 50 cGy groups at 8 week. Supplementation with ALA mitigated the early effects, but not the ultimate depletion of ovarian follicles. In conclusion, oxygen charged particles are even more potent inducers of ovarian follicle depletion than charged iron particles, raising concern for premature ovarian failure in astronauts exposed to both particles during space travel.


Asunto(s)
Ovario/efectos de la radiación , Ovulación/efectos de la radiación , Radioisótopos de Oxígeno/efectos adversos , Insuficiencia Ovárica Primaria/etiología , Dosis de Radiación , Exposición a la Radiación/efectos adversos , Traumatismos por Radiación/etiología , Animales , Antioxidantes/farmacología , Apoptosis/efectos de la radiación , Astronautas , Daño del ADN , Relación Dosis-Respuesta en la Radiación , Ciclo Estral/sangre , Ciclo Estral/efectos de la radiación , Femenino , Hormona Folículo Estimulante/sangre , Histonas/metabolismo , Humanos , Transferencia Lineal de Energía , Peroxidación de Lípido/efectos de la radiación , Hormona Luteinizante/sangre , Ratones Endogámicos C57BL , Ovario/efectos de los fármacos , Ovario/fisiopatología , Ovulación/efectos de los fármacos , Estrés Oxidativo/efectos de la radiación , Fosforilación , Insuficiencia Ovárica Primaria/sangre , Insuficiencia Ovárica Primaria/fisiopatología , Traumatismos por Radiación/sangre , Traumatismos por Radiación/fisiopatología , Medición de Riesgo , Vuelo Espacial , Ácido Tióctico/farmacología , Factores de Tiempo
11.
J Clin Endocrinol Metab ; 102(7): 2242-2250, 2017 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-28368472

RESUMEN

Context: Long-term follow-up data on premature ovarian insufficiency (POI) in childhood cancer survivors are limited. Objective: To describe the prevalence of POI, its risk factors, and associated long-term adverse health outcomes. Design: Cross-sectional. Setting: The St. Jude Lifetime Cohort Study, an established cohort in a tertiary care center. Patients: Nine hundred twenty-one participants (median age, 31.7 years) were evaluated at a median of 24.0 years after cancer diagnosis. Main Outcome Measure: POI was defined by persistent amenorrhea combined with a follicle-stimulating hormone level >30 IU/L before age 40. Multivariable Cox regression was used to study associations between demographic or treatment-related risk factors and POI. Multivariable logistic regression was used to study associations between POI and markers for cardiovascular disease, bone mineral density (BMD), and frailty. Exposure to alkylating agents was quantified using the validated cyclophosphamide equivalent dose (CED). Results: The prevalence of POI was 10.9%. Independent risk factors for POI included ovarian radiotherapy at any dose and CED ≥8000 mg/m2. Patients with a body mass index ≥30 kg/m2 at the time of the St. Jude Lifetime Cohort assessment were less likely to have a diagnosis of POI. Low BMD and frailty were independently associated with POI. Conclusion: High-dose alkylating agents and ovarian radiotherapy at any dose are associated with POI. Patients at the highest risk should be offered fertility preservation whenever feasible. POI contributes to poor general health outcomes in childhood cancer survivors; further studies are needed to investigate the role of sex hormone replacement in improving such outcomes.


Asunto(s)
Neoplasias/terapia , Insuficiencia Ovárica Primaria/etiología , Sobrevivientes , Adolescente , Adulto , Antineoplásicos Alquilantes/efectos adversos , Antineoplásicos Alquilantes/uso terapéutico , Índice de Masa Corporal , Estudios de Cohortes , Estudios Transversales , Femenino , Humanos , Persona de Mediana Edad , Neoplasias/epidemiología , Osteoporosis/epidemiología , Osteoporosis/etiología , Ovario/efectos de la radiación , Paridad , Prevalencia , Insuficiencia Ovárica Primaria/epidemiología , Dosis de Radiación , Radioterapia/efectos adversos , Factores de Riesgo , Tennessee/epidemiología , Adulto Joven
12.
Cancer Med ; 6(3): 508-515, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-28211638

RESUMEN

In this study, the relationship between ovarian function and ovarian limited dose in radiotherapy was evaluated in young patients with cervical cancer who underwent ovarian transposition (Fig1B). Moreover, the novel ovarian dose limit for a better preservation of ovarian function in intensity-modulated radiation therapy (IMRT) was determined. We retrospectively analyzed data from 86 patients with cervical cancer who received radical hysterectomy and ovarian transposition from January 2013 to June 2015. In agreement with the National Comprehensive Cancer Network Guidelines (NCCN) for Cervical Cancer Version 2.2015, 65 patients with pathological high-risk factors were administered adjuvant radiotherapy-20 of them received three-dimensional conformal radiotherapy (Observation Group A), 24 patients received IMRT with no limitation on radiation dose to ovaries (Observation Group B), and 21 patients underwent IMRT with limited radiation dose(V10 <20%) to ovaries (Observation Group C). Twenty-one patients without any predetermined high-risk factors did not received radiation therapy (Control Group D). Patients from all four groups were followed up, and sex hormone levels (E2 , P, follicle-stimulating hormone [FSH], LH) before radiation, postradiation, 3 month, and 6 month after the radiation therapy were measured by electrochemiluminescence immunoassay. Subsequently, changes in sex hormone levels in all four groups of patients at various time points were analyzed. The levels of sexual hormones (E2 , P, FSH, LH) before radiation, postradiation, 3 month, and 6 month after the radiation therapy in patients from all three observation groups were significantly lower than those in patients of the control group (P < 0.05). There was no statistically significant difference in the levels of sex hormones in patients of the control group at different time points (P > 0.05). Within each observation group, there was a statistically significant difference in the sex hormone levels in patients before the radiation and after the radiation (P < 0.05); however, when data from all three observation groups were compared, only the difference in the levels of FSH and LH between the patients from Group A and Group C was statistically significant (P < 0.05). The results of receiver-operating characteristic (ROC) curve analysis suggested that limiting ovarian radiation dose to V7.5  < 26% in IMRT prevents the disruption of ovarian function (area under ROC curve was 0.740, confidence interval [CI] = 0.606-0.874). In young patients with cervical cancer who underwent radical hysterectomy and ovarian transposition without receiving adjuvant radiotherapy, ovarian endocrine function was well preserved. In patients who received any type of postoperative radiotherapy, ovarian function was affected, suggesting that the standard ovarian limited dose used in IMRT disrupted ovarian function. The results of the ROC curve analysis suggested that the new optimal dose limit of V7.5  < 26% should be used in IMRT to preserve ovarian function (P = 0.003).


Asunto(s)
Hormona Folículo Estimulante/metabolismo , Hormona Luteinizante/metabolismo , Ovario/fisiología , Neoplasias del Cuello Uterino/radioterapia , Adulto , Femenino , Estudios de Seguimiento , Humanos , Histerectomía , Masculino , Órganos en Riesgo/fisiología , Ovario/metabolismo , Ovario/efectos de la radiación , Curva ROC , Dosificación Radioterapéutica , Radioterapia Adyuvante/efectos adversos , Radioterapia de Intensidad Modulada/efectos adversos , Neoplasias del Cuello Uterino/metabolismo , Neoplasias del Cuello Uterino/cirugía
13.
J Pediatr Adolesc Gynecol ; 25(4): 262-6, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22840937

RESUMEN

OBJECTIVE: The purpose of this study was to investigate the ovarian protective effects of resveratrol in rats exposed to total body irradiation. DESIGN: Experimental study. SETTINGS: University hospital. PARTICIPANTS AND INTERVENTIONS: Thirty female rats were randomized into four groups: (1) control group (n = 7); (2) low-dose (10 mg/kg) resveratrol group (n = 8); (3) high-dose (100 mg/kg) resveratrol group (n =7); and (4) sham irradiation group (n = 8). The drugs were administered intraperitoneally as single doses, and the rats were exposed to total body radiation 24 h after the treatment. The animals were sacrificed the following day, and their ovaries were excised for histopathological and biochemical analysis. MAIN OUTCOME MEASURES: The ovarian follicle counts were calculated, and irradiation-dependent ovarian damage and tissue levels of antioxidant enzymes were evaluated. RESULTS: Group 2 and Group 3 showed significantly higher numbers of total follicle counts compared with Group 1 (P < 0.01). The low-dose resveratrol treatment was associated with significantly higher numbers of primary follicles than the high-dose group. The tissue activities of glutathione peroxidase (GsH-Px) and catalase (CAT) were significantly elevated in the resveratrol-treated animals. Evaluation of ovarian histology revealed no remarkable changes in fibrosis and leucocyte infiltration among the resveratrol-treated and control rats; however, vascularity was significantly reduced in the high-dose group (P = 0.014). CONCLUSION: Resveratrol attenuated irradiation-dependent ovarian damage, suggesting that this natural antioxidant is effective in reducing the follicle loss induced by ionizing radiation.


Asunto(s)
Antioxidantes/uso terapéutico , Ovario/efectos de la radiación , Traumatismos por Radiación/prevención & control , Estilbenos/uso terapéutico , Animales , Antioxidantes/farmacología , Catalasa/efectos de los fármacos , Catalasa/metabolismo , Femenino , Glutatión Peroxidasa/efectos de los fármacos , Glutatión Peroxidasa/metabolismo , Malondialdehído/metabolismo , Folículo Ovárico/efectos de los fármacos , Folículo Ovárico/efectos de la radiación , Ovario/irrigación sanguínea , Ovario/enzimología , Ovario/patología , Traumatismos por Radiación/enzimología , Traumatismos por Radiación/inmunología , Traumatismos por Radiación/patología , Ratas , Ratas Wistar , Resveratrol , Estadísticas no Paramétricas , Estilbenos/farmacología
14.
J Radiat Res ; 53(3): 377-84, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22739007

RESUMEN

This two-generation study evaluated the effects of depleted uranium (DU) on reproduction in rats. Across two generations, Wistar rats (30/sex/group) were maintained on feed containing DU at dose levels of 0 (control group), 4 (DU4 group), or 40 (DU40 group) mg kg⁻¹ day⁻¹ for 4 months prior to mating. After 4 months of exposure, the pregnancy rate, normal labour rate, and survival rate of offspring produced by F1 rats were all significantly decreased as compared to the control group, and especially in the DU40 group, these parameters fell by half to two-thirds, while no adverse effects were evident in F0 rats. The uranium content in the testes and ovaries of F1 rats in the DU4 and DU40 groups was significantly higher than that found in F0 rats. The levels of sex hormone in the serum were disorder in both generations. The enzymes related to spermiogenesis were also significantly different between generations, and the damage was more severe in F1 rats. In conclusion, the reproductive effects in F0 rats were slight after chronic oral exposure to DU, while the effects were obvious in F1 rats.


Asunto(s)
Reproducción/efectos de la radiación , Uranio/toxicidad , Administración Oral , Animales , Relación Dosis-Respuesta en la Radiación , Femenino , Hormonas Esteroides Gonadales/sangre , Masculino , Ovario/efectos de la radiación , Embarazo , Ratas , Ratas Wistar , Espermatogénesis/efectos de la radiación , Testículo/efectos de la radiación , Uranio/administración & dosificación , Uranio/farmacocinética
15.
J Gynecol Obstet Biol Reprod (Paris) ; 39(8 Suppl): F71-8, 2010 Dec.
Artículo en Francés | MEDLINE | ID: mdl-21074336

RESUMEN

The discovery of breast cancer carcinoma sensitivity to estradiol (E) suppression is the starting point of hormonal treatment. Hormonal receptors (ER and PR) are the pathway of the action of estradiol on breast tumor cells. The detection of at least one of these two receptors is needed to classify a tumor as hormone sensitive. The hormonal treatment of breast cancer attempts to suppress the stimulating action of E on tumor cells. This can be done by decreasing E synthesis--ovarian suppression (OS) or aromatase inhibitors (AIs)--or by compelling with E on receptors--tamoxifen (TAM). In advanced breast cancer, hormonal treatment gives good response with few side effects. In young patient, the treatment is based on TAM. It could be associated with OS. In post-menopausal women, AIs are more potent than TAM. They are used in the first line treatment and TAM as a second line. Fulvestrant is not superior TAM or AIs. In the adjuvant setting, hormonal treatment gives a significant reduction of recurrence and death. In young patient, the treatment is based on TAM. It could be associated with OS. In post-menopausal patients, adjuvant treatment must include an AIs for at least one part of the treatment. A survey of bone density is necessary.


Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Factores de Edad , Inhibidores de la Aromatasa/uso terapéutico , Densidad Ósea , Neoplasias de la Mama/química , Neoplasias de la Mama/terapia , Quimioterapia Adyuvante , Antagonistas de Estrógenos/uso terapéutico , Femenino , Hormona Liberadora de Gonadotropina/análogos & derivados , Humanos , Ovario/efectos de los fármacos , Ovario/efectos de la radiación , Ovario/cirugía , Posmenopausia , Receptores de Estrógenos/análisis , Receptores de Progesterona/análisis , Tamoxifeno/uso terapéutico
16.
Clin Exp Obstet Gynecol ; 37(4): 328-30, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-21355471

RESUMEN

BACKGROUND: Radioactive iodine has been used effectively in the diagnosis and treatment of thyroid diseases. Since radiation is delivered to the whole body, including the ovaries, there is reasonable concern as to whether there is a possibility of mutagenic effect on germ cells. CASE REPORT: A 33-year-old woman with a differentiated papillary carcinoma. (T2N0M0), underwent radiotherapy three weeks after surgery and one year afterwards she became pregnant. At the 38th week of gestation she delivered vaginally a healthy female neonate weighing 3100 g. The child at the age of five years is healthy with no signs of malignancy or other disease. DISCUSSION: Washout of 131I of the whole body takes place in a few days. Nevertheless, most guidelines recommend avoiding pregnancy for four to six or even 12 months after RAI treatment or scanning. As reported in our case a normal uncomplicated pregnancy can follow an operative and complementary treatment of thyroid cancer.


Asunto(s)
Carcinoma Papilar/radioterapia , Radioisótopos de Yodo/efectos adversos , Radioisótopos de Yodo/uso terapéutico , Resultado del Embarazo , Neoplasias de la Tiroides/radioterapia , Adulto , Carcinoma Papilar/cirugía , Femenino , Estudios de Seguimiento , Humanos , Recién Nacido , Ovario/efectos de la radiación , Embarazo , Efectos Tardíos de la Exposición Prenatal , Neoplasias de la Tiroides/cirugía , Tiroidectomía
17.
Oncology (Williston Park) ; 23(1): 27-33, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19283918

RESUMEN

Endocrine therapy remains pivotal in the adjuvant therapy of premenopausal women with hormone receptor-positive breast cancer. Ovarian ablation, used alone, is effective in delaying recurrence and increasing survival in such women. When added to chemotherapy, it is less clear that this technique is effective, perhaps because of the endocrine ablative effect of chemotherapy. Adjuvant trials comparing ovarian ablation with or without tamoxifen to CMF-type chemotherapy (cyclophosphamide, methotrexate, fluorouracil) suggest that the endocrine therapy is equivalent to or better than this chemotherapy in women whose tumors express estrogen and/or progesterone receptors. Endocrine therapy with ovarian ablation, tamoxifen, or the combination is also useful in the metastatic setting in premenopausal women.


Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Ovario/efectos de los fármacos , Premenopausia , Receptores de Estrógenos/análisis , Adulto , Antineoplásicos Hormonales/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Inhibidores de la Aromatasa/uso terapéutico , Neoplasias de la Mama/química , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante , Ciclofosfamida/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Hormona Liberadora de Gonadotropina/análogos & derivados , Hormona Liberadora de Gonadotropina/uso terapéutico , Goserelina/efectos adversos , Goserelina/uso terapéutico , Humanos , Menopausia Prematura/efectos de los fármacos , Metotrexato/administración & dosificación , Persona de Mediana Edad , Ovariectomía , Ovario/efectos de la radiación , Calidad de Vida , Tamoxifeno/efectos adversos , Tamoxifeno/uso terapéutico
18.
Photomed Laser Surg ; 27(2): 325-35, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18800945

RESUMEN

OBJECTIVE: The objective of this study is to evaluate the efficacy of laser-induced fluorescence (LIF) data obtained at 325-nm pulsed laser excitation for the discrimination of normal, benign, and malignant ovarian tissues. BACKGROUND DATA: Several studies have reported that the autofluorescence technique has a high specificity and sensitivity for discrimination between diseased and non-diseased tissues of various cancers, and also has the advantages of being non-invasive and producing a real-time diagnosis. When using this technique on ovarian tissues in most of the previously reported studies, multivariate statistical tools were used and classification analyses were carried out. MATERIALS AND METHODS: Autofluorescence spectra of normal, benign, and malignant ovarian tissues were recorded with 325-nm pulsed laser excitation in the spectral region from 350-600 nm in vitro. The spectral analysis for discrimination between the different types of tissues was carried out using principal component analysis (PCA)-based non-parametric k-nearest neighbor (k-NN) analysis. RESULTS: A total of 97 (34 normal, 33 benign, and 30 malignant) spectra were obtained from 22 subjects with normal, benign, and malignant tissues. The discrimination analysis of data using a PCA-based k-NN algorithm showed very good discrimination. The performance of the analysis was evaluated by calculating statistical parameters, specificity, sensitivity, and accuracy and were found to be 100%, 90.90%, and 94.2%, respectively. CONCLUSION: The results show that the discrimination of normal, benign, and malignant ovarian conditions can be achieved quite successfully using LIF.


Asunto(s)
Endometriosis/diagnóstico , Fluorescencia , Terapia por Luz de Baja Intensidad , Neoplasias Ováricas/diagnóstico , Ovario/efectos de la radiación , Espectrometría de Fluorescencia/métodos , Algoritmos , Femenino , Humanos , Rayos Láser , Ovario/patología , Proyectos Piloto , Análisis de Componente Principal
19.
Acta Oncol ; 47(4): 709-17, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18465339

RESUMEN

INTRODUCTION: A cohort of premenopausal patients with primary hormone receptor positive breast cancer was prospectively identified to be eligible for the DBCG 89B trial. We perform a long-term follow-up and evaluate the external validity of the trial. MATERIAL AND METHODS: Following registration in a population-based registry, patients were invited to be randomized to ovarian ablation (OA) versus nine courses of three-weekly cyclophosphamide, methotrexate and 5-fluorouracil (CMF). The same procedures were used in all patients, including report forms, central review, querying, and analysis of data. Multivariate analysis was used to adjust for differences in base-line characteristics. RESULTS: Participation in the randomization varied according to center and time period. One thousand six hundred and twenty eight eligible patients were registered and 525 randomized in the DBCG 89B trial. Median estimated follow-up was 9.5 years for disease-free survival and 12.1 years for overall survival. Non-enrolled patients had a disease-free and overall survival similar to randomized patients. Within 5 years of surgery, results were similar following OA and CMF, but disease-free survival was significant inferior with OA more than five years after surgery, adjusted hazard ratio 1.38 (95% CI 1.03 to 1.85; p=0.03). This convened ten years after surgery to an inferior survival with OA, and the adjusted hazard ratio was 2.37 (95% CI 1.43 to 3.91; p<0.01). DISCUSSION: This prospective cohort study indicates that eligible patients not participating in the DBCG 89B trial had a similar disease-free and overall survival as participants. Survival was similar after OA and CMF in the first ten years, but became inferior in the OA group 10 or more years after surgery.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/terapia , Ovario/fisiología , Adolescente , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante , Estudios de Cohortes , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Femenino , Fluorouracilo/administración & dosificación , Fluorouracilo/efectos adversos , Estudios de Seguimiento , Humanos , Metotrexato/administración & dosificación , Metotrexato/efectos adversos , Persona de Mediana Edad , Ovariectomía , Ovario/efectos de la radiación , Ovario/cirugía , Tasa de Supervivencia , Resultado del Tratamiento
20.
J Clin Oncol ; 24(31): 4956-62, 2006 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-17075113

RESUMEN

PURPOSE: To compare the efficacy of ovarian ablation versus chemotherapy in early breast cancer patients with hormone receptor-positive disease. PATIENTS AND METHODS: We conducted an open, randomized, multicenter trial including premenopausal breast cancer patients with hormone receptor-positive tumors and either axillary lymph node metastases or tumors with a size of 5 cm or more. Patients were randomly assigned to ovarian ablation by irradiation or to nine courses of chemotherapy with intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) administered every 3 weeks. RESULTS: Between 1990 and May 1998, 762 patients were randomly assigned, and the present analysis is based on 358 first events. After a median follow-up time of 8.5 years, the unadjusted hazard ratio for disease-free survival in the ovarian ablation group compared with the CMF group was 0.99 (95% CI, 0.81 to 1.22). After a median follow-up time of 10.5 years, overall survival (OS) was similar in the two groups, with a hazard ratio of 1.11 (95% CI, 0.88 to 1.42) for the ovarian ablation group compared with the CMF group. CONCLUSION: In this study, ablation of ovarian function in premenopausal women with hormone receptor-positive breast cancer had a similar effect to CMF on disease-free and OS. No significant interactions were demonstrated between treatment modality and hormone receptor content, age, or any of the well-known prognostic factors.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/radioterapia , Neoplasias Hormono-Dependientes/tratamiento farmacológico , Neoplasias Hormono-Dependientes/radioterapia , Ovario/efectos de la radiación , Premenopausia , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/cirugía , Quimioterapia Adyuvante , Ciclofosfamida/administración & dosificación , Supervivencia sin Enfermedad , Esquema de Medicación , Femenino , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Humanos , Metotrexato/administración & dosificación , Persona de Mediana Edad , Neoplasias Hormono-Dependientes/metabolismo , Neoplasias Hormono-Dependientes/cirugía , Oportunidad Relativa , Radioterapia Adyuvante , Análisis de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA